| scholarly article | Q13442814 |
| P2093 | author name string | Ken Kato | |
| Yasuhide Yamada | |||
| Hirokazu Taniguchi | |||
| Naoki Takahashi | |||
| Tetsuya Hamaguchi | |||
| Yasuhiro Shimada | |||
| Koh Furuta | |||
| Satoru Iwasa | |||
| Yusuke Sasaki | |||
| Yoshitaka Honma | |||
| Hirokazu Shoji | |||
| Atsuo Takashima | |||
| Natsuko Okita | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays | Q83789922 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer | Q33682988 | ||
| HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development | Q33917507 | ||
| High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients | Q34221586 | ||
| The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities | Q34399306 | ||
| HGF rescues colorectal cancer cells from EGFR inhibition via MET activation | Q34550898 | ||
| Treatment options in patients with metastatic gastric cancer: current status and future perspectives | Q34661367 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome | Q36089948 | ||
| Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer | Q36184256 | ||
| MET amplification as a potential therapeutic target in gastric cancer. | Q36984821 | ||
| Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells | Q37141943 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors | Q37316206 | ||
| Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). | Q37632143 | ||
| Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects | Q37724647 | ||
| Resistance to human epidermal growth factor receptor type 2-targeted therapies | Q38181766 | ||
| Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer | Q38980193 | ||
| Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours | Q39250672 | ||
| MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | Q39413378 | ||
| Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer | Q39499360 | ||
| Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells | Q40006240 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion | Q40490783 | ||
| An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. | Q41503051 | ||
| Rapamycin in preventive (very low) doses | Q42558709 | ||
| HGF-MET as a breast cancer biomarker | Q43228470 | ||
| Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells | Q43539817 | ||
| Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer | Q44764084 | ||
| Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers | Q46068781 | ||
| Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. | Q46458791 | ||
| Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer | Q46839142 | ||
| HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. | Q50761028 | ||
| HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. | Q50889414 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. | Q54218339 | ||
| Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. | Q54341358 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. | Q55071600 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 4925-4938 | |
| P577 | publication date | 2015-12-24 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer | |
| P478 | volume | 7 |
| Q57176090 | Biomarkers of gastric cancer: Current topics and future perspective |
| Q89842618 | Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer |
| Q42700876 | Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer |
| Q89687522 | Clinical significance of various growth factors in patients with different gastric neoplasms |
| Q47932548 | Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy |
| Q37735624 | Hepatocyte growth factor/MET in cancer progression and biomarker discovery |
| Q89795555 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives |
| Q37745875 | Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer |
| Q52657273 | The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. |
Search more.